Has Covid-19 reduced the management of end-stage kidney disease in 2020?

Authors

  • Jacobs Lucas Pierre-michel CHU Brugmann, Bruxelles
  • Frederic Collart CHU Brugmann, Bruxelles https://orcid.org/0000-0003-1673-5450
  • Thomas Baudoux CHU Erasme, Bruxelles
  • Catherine Bonvoisin CHU Sart-Tilman, Liège
  • Jean-Marc De Smet CHU Charleroi
  • Arnaud Devresse UCL Saint Luc, Brussels
  • Joseph Mbaba Mena CHR Mons-Hainaut, Mons
  • Luc Radermacher CHR Citadelle, Liège
  • Jean-Marin des Grottes CHU du Tivoli, La Louvière

DOI:

https://doi.org/10.25796/bdd.v4i1.61453

Keywords:

Incidence rate, dialysis, SARS-COv2, Covid-19

Abstract

The SARS-CoV-2 pandemic has been associated with a drop in diagnoses of several diseases in 2020, including cancers. In this letter addressed to the editor, the Groupement des Néphrologues Francophones de Belgique (GNFB), assessed whether there was a similar effect concerning end-stage renal disease (ESRD).

Data of patients with ESRD form 25 of the 26 centers constituting the GNFB register were collected. In conclusion, the year 2020 was marked by an 8% drop in the incidence of overall treatments for ESRD. A particularly marked decline in outpatient dialysis initiation programs (PD and HDD). In addition, the interruption of transplant programs in academic centers as well as the closure of ambulatory patient clinics in a majority of hospitals was associated with a delay in nephrological management.

Published

2021-04-07

How to Cite

1.
Lucas Pierre-michel J, Collart F, Baudoux T, Bonvoisin C, De Smet J-M, Devresse A, Mbaba Mena J, Radermacher L, des Grottes J-M. Has Covid-19 reduced the management of end-stage kidney disease in 2020? . Bull Dial Domic [Internet]. 2021 Apr. 7 [cited 2024 Feb. 28];4(1):53-4. Available from: https://www.bdd.rdplf.org/index.php/bdd/article/view/61453